Omega-3 Cancer Survival Research: The EMT2 Trial
Table of Contents
Abstract: The phase 3 EMT2 trial produced a seemingly contradictory result: high-dose prescription EPA did not significantly delay colorectal cancer progression, yet patients assigned EPA had better overall survival after liver metastasis surgery. This article explains why progression-free survival and overall survival can diverge, reviews hypotheses involving inflammation resolution, immune regulation, skeletal-muscle metabolism, and ALOX15, and shows how evidence-informed nutrition and rehabilitation can support patients without being confused with cancer treatment.
Scientific studies do not always produce a simple “worked” or “did not work” answer. Sometimes the most important discovery appears between endpoints.
The EPA for Metastasis Trial 2, or EMT2, studied 418 patients undergoing potentially curative liver resection for colorectal cancer metastases. Participants received either 4 grams daily of high-purity prescription icosapent ethyl, an EPA formulation, or mineral-oil placebo before surgery and for two to four years afterward (Cockbain et al., 2023).
The primary endpoint was progression-free survival. It did not significantly improve: median progression-free survival was 13.5 months with EPA and 12.9 months with placebo. Yet five-year overall survival, a prespecified key secondary endpoint, was 62.0% with EPA versus 45.1% with placebo, with an adjusted hazard ratio for death of 0.68 (ASCO Post, 2026).
That does not prove EPA stopped tumors. It shows that two valid cancer outcomes can move differently.
Progression-free survival asks how long patients live before cancer grows, returns, or another qualifying progression event occurs. Overall survival asks how long patients remain alive.
A therapy could theoretically influence the body’s ability to tolerate disease, surgery, later treatment, inflammation, infection, cardiovascular stress, or muscle loss without substantially changing when a scan first documents progression.
EMT2, therefore, should not be described as a trial in which EPA “prevented recurrence.” The primary endpoint was negative. The appropriate interpretation is narrower: EPA was associated with better overall survival despite no statistically significant improvement in progression-free survival (ASCO Post, 2026).
The primary endpoint is the outcome that a trial is primarily designed and powered to test. Missing it matters, and researchers should resist turning a secondary finding into routine practice.
However, overall survival is one of oncology’s most important outcomes. EMT2’s survival signal was statistically significant and directionally consistent in sensitivity analyses. The finding therefore creates a serious scientific question: why did survival improve when progression timing did not?
The responsible response is neither “EPA cures cancer” nor “the trial failed, so nothing matters.” The main progression hypothesis was not confirmed, but an important survival observation emerged that requires mechanistic analysis, replication, and full peer-reviewed reporting.
EPA can become incorporated into cell membranes and serve as a substrate for lipid mediators involved in inflammatory regulation. One hypothesis is that EPA may influence how the host resolves inflammation rather than simply attacking cancer cells.
Persistent inflammatory signaling can affect appetite, energy use, muscle protein turnover, insulin signaling, fatigue, and immune behavior. Specialized pro-resolving mediators, including resolvins derived from omega-3 fatty acids, help coordinate the transition from active inflammation toward resolution and tissue repair.
This is biologically plausible, but EMT2 has not proven that inflammation resolution caused the survival difference.
EMT2 investigators have also discussed host antitumor immunity as a possible explanation. Immune surveillance depends on communication among T cells, macrophages, tumor cells, gut microbes, cytokines, and metabolic signals.
Preclinical research offers clues. Zuo and colleagues found that intestinal expression of 15-lipoxygenase-1, encoded by ALOX15, changed how EPA and DHA affected colorectal tumorigenesis in mice. With ALOX15 expression, omega-3 exposure increased resolvin production, reduced several inflammatory cytokines and chemokines, decreased tumor-associated macrophages, and increased CD8-positive T-cell abundance (Zuo et al., 2025).
These findings come from animal models. They may not explain EMT2, but they provide a testable framework.
ALOX15 helps convert polyunsaturated fatty acids into bioactive lipid mediators. Think of EPA as raw material and ALOX15 as part of the machinery that decides what the body can build from it.
The 2025 Zuo study found that EPA and DHA had variable effects in mice without transgenic human ALOX15 expression, while ALOX15 expression was associated with greater resolvin generation and more consistent suppression of colorectal tumor formation.
ALOX15 is not a validated clinical biomarker for selecting patients for high-dose EPA. The research instead suggests that enzyme expression, formulation, dose, genetics, and tissue context may help explain why omega-3 studies can produce different results.
Cancer cachexia involves involuntary weight loss, muscle wasting, altered appetite, inflammation, and metabolic disruption. It is not simply caused by insufficient intake. Disease signaling can change how the body uses fuel and regulates muscle protein.
A 2026 preclinical study found that EPA and other long-chain polyunsaturated fatty acids reduced colorectal-cancer-cell-induced muscle wasting in laboratory muscle cells through a 15-lipoxygenase-dependent pathway (Lu et al., 2026).
That does not prove EPA prevented cachexia in EMT2. Still, preserving muscle could theoretically support mobility, treatment tolerance, respiratory reserve, metabolic stability, and recovery capacity. Human clinical confirmation is required.
EMT2 does not show that over-the-counter fish oil reproduces the trial result. The study used 4 grams daily of prescription high-purity icosapent ethyl. Formulation and dose matter.
EPA also should not replace surgery, chemotherapy, targeted therapy, immunotherapy, radiation, or oncology follow-up. Patients should not independently start high-dose EPA after cancer surgery based on headlines. Medication interactions, bleeding risk, cardiovascular history, surgical timing, nutrition status, and the oncology plan require professional review.
The useful integrative lesson is broader than one supplement: measure the patient, not just the product.
Clinical biomarker interpretation may include nutrition status, lipids, glucose control, liver function, weight change, and muscle loss when medically appropriate. Nutrition planning can emphasize adequate protein, energy intake, hydration, and food tolerance. Rehabilitation can address deconditioning, weakness, altered gait, pain, sleep disruption, and fear of movement.
Chiropractic care, acupuncture, electroacupuncture, and other conservative approaches may support appropriately screened musculoskeletal symptoms or pain-management goals. They should never be represented as antitumor therapies. Oncology remains responsible for cancer-directed treatment.
At Injury Medical Chiropractic and Functional Medicine Clinic in El Paso, Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, works in a multidisciplinary model that combines physical medicine, functional nutrition, laboratory interpretation, and rehabilitation. Medical Director Dr. Maria Guadalupe Cardenas, MD, a board-certified internal medicine physician, supports medical oversight, advanced laboratory review, risk stratification, and coordination across complex cases.
The team includes nurse-practitioner care with experience in soft-tissue injury and recovery. This structure helps separate supportive musculoskeletal and metabolic care from disease-specific medical treatment. The clinic is among the limited multidisciplinary practices in El Paso offering this combination of chiropractic, medical oversight, functional medicine, acupuncture, rehabilitation, and advanced supportive therapies.
Relevant patient education on Dr. Jimenez’s website includes Physician-Led Integrative Chiropractic Care in El Paso, Physician-Led Integrative Chiropractic Care in El Paso, IV Infusion Therapy: A Functional Medicine Overview IV Infusion Therapy: A Functional Medicine Overview, and Immune Dysfunction and Inflammation Immune Dysfunction and Inflammation. These pages emphasize screening, scope, coordinated care, and individualized decision-making.
For cancer survivors, every supportive intervention should be cross-verified with oncology and the patient’s primary medical team.
EMT2 matters precisely because it complicates the story. The trial did not show a statistically significant delay in progression, yet it showed a meaningful overall-survival signal. That pattern invites questions about immunity, inflammation resolution, muscle preservation, metabolism, later treatment tolerance, and ALOX15-dependent lipid biology.
Those mechanisms remain hypotheses, not clinical conclusions. The responsible next step is deeper analysis of EMT2 biospecimens, peer-reviewed reporting, replication, and biomarker research. Until then, EPA should be discussed as an intriguing investigational adjunct in this cancer setting, not a proven cancer therapy.
For patients, the practical message is simple: ask what an endpoint means, ask whether a proposed mechanism has been proven in humans, and ask how nutrition and rehabilitation can fit safely beside standard oncology care.
If you are recovering from major illness, surgery, or cancer treatment and need help addressing mobility, pain, nutrition, metabolic health, or deconditioning, a coordinated evaluation may identify supportive options that fit your medical plan. Dr. Jimenez’s team emphasizes evidence-informed rehabilitation, biomarker-guided wellness, and communication with physicians and specialists. Always review supplements, IV therapies, manual care, and exercise plans with your oncology and primary-care teams before making changes during recovery.
ASCO Post. (2026, October 26). Omega-3 EPA linked to longer survival after surgery for colorectal cancer liver metastases. Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases
Cockbain, A. J., et al. (2023). Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 study protocol. BMJ Open, 13, e077427. EPA for Metastasis Trial 2 Study Protocol
Lu, X., Maddipati, K. R., & Markworth, J. F. (2026). Long-chain polyunsaturated fatty acids mitigate in vitro skeletal muscle wasting induced by colorectal carcinoma cells via a 15-LOX-dependent pathway. bioRxiv. Long-Chain Polyunsaturated Fatty Acids and Skeletal Muscle Wasting
Zuo, X., Kiyasu, Y., Liu, Y., et al. (2025). Colorectal 15-lipoxygenase-1 as a host factor determining the effects of eicosapentaenoic acid and docosahexaenoic acid on colorectal tumorigenesis in mice. Cellular and Molecular Gastroenterology and Hepatology, 19(12), 101607. Colorectal 15-Lipoxygenase-1 as a Host Factor
by Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST Read More
Concussion and Whiplash Headaches: What Does Scientific Research Tell Us? Two Accidents, Two Mechanisms, Surprisingly… Read More
By Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST Read More
Permanent Impairment vs. Persistent Pain: Why Scientific Measurement Matters Two patients leave the same rear-end… Read More
By Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST Read More
What ICHD-3 and Current Guidelines Require When Differentiating Migraine, Cluster, Cervicogenic, and Post-Traumatic Headaches Imagine… Read More
Personal Injury, Trauma & Spine Rehab Specialists